Related Experiment Videos
Mucus and MUC in asthma
Esteban J Morcillo1, Julio Cortijo
1Department of Pharmacology, Faculty of Medicine, University of Valencia, and Research Foundation of University General Hospital Consortium, Valencia, Spain. esteban.morcillo@uv.es
Current Opinion in Pulmonary Medicine
|December 17, 2005
Summary
Excess mucus in asthma, often overlooked, significantly impacts airflow and severity. Targeting mucus hypersecretion pathways, like the epidermal growth factor receptor (EGFR), offers new therapeutic strategies for asthma management.
Area of Science:
- Pulmonary Medicine
- Respiratory Physiology
- Molecular Biology
Background:
- Asthma involves chronic airway inflammation and mucus hypersecretion.
- Mucus plugging is a significant factor in asthma severity, airflow limitation, and mortality.
- The role of mucus hypersecretion in asthma has been historically underestimated compared to inflammation.
Purpose of the Study:
- To review recent findings on mucus hypersecretion in asthma.
- To explore therapeutic avenues for controlling mucus hypersecretion.
- To highlight the importance of mucus plugging in asthma pathophysiology.
Main Methods:
- Review of current literature on asthma mucus hypersecretion.
- Analysis of molecular mechanisms underlying mucin gene expression and regulation.
- Investigation of signaling pathways involved in mucus secretion, including EGFR.
Main Results:
- A distinct mucus hypersecretory phenotype is observed in asthma.
- Overexpression of MUC5AC, MUC5B, and MUC2 mucins is noted in asthma secretions.
- Epidermal growth factor receptor (EGFR) activation is central to stimuli-induced mucin secretion; crosstalk with other receptors is implicated.
Conclusions:
- Airway mucus hypersecretion is a key component of airway remodeling in asthma.
- Further research into pathophysiology and therapeutics for mucus hypersecretion is essential.
- Targeting the EGFR cascade may lead to novel antihypersecretory drugs for improved asthma treatment.